ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-TREM2 Monoclonal Antibody EOS006215

Its studies are mostly in Neoplasms, led by iTeos Belgium.

Furthest: phase 1, since Mar 10, 20251 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
iTeos Belgium10 open or runningphase 1since Mar 10, 2025Mar 10, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 10, 2025First study: phase 1 study in NeoplasmsFirst studyNCT06877533 · 3 enrolled · United States

TargetBeta

TREM2 →read by rule
“A human monoclonal antibody targeting triggering receptor expressed on myeloid cells 2 (TREM2; TREM-2), ”NCIt, by rule

Other programs on TREM2

ProgramCompanyFurthest phaseStudies
SAR448851Sanofiphase 21

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06877533Neoplasms · United States1TerminatedJul 10, 20253

How it is read

Names in the registry

  • “EOS006215”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.